Literature DB >> 28854701

Aqua-soluble DDQ reduces the levels of Drp1 and Aβ and inhibits abnormal interactions between Aβ and Drp1 and protects Alzheimer's disease neurons from Aβ- and Drp1-induced mitochondrial and synaptic toxicities.

Chandra Sekhar Kuruva1, Maria Manczak1, Xiangling Yin1, Gilbert Ogunmokun1,2, Arubala P Reddy2, P Hemachandra Reddy1,3,4,5,6,7,8.   

Abstract

The purpose of our study was to develop a therapeutic target that can reduce Aβ and Drp1 levels, and also can inhibit abnormal interactions between Aβ and Drp1 in AD neurons. To achieve this objective, we designed various compounds and their 3-dimensional molecular structures were introduced into Aβ and Drp1 complex and identified their inhibitory properties against Aβ-Drp1 interaction. Among all, DDQ was selected for further investigation because of 1) its best docking score and 2) its binding capability at interacting sites of Drp1 and Aβ complex. We synthesized DDQ using retro-synthesis and analyzed its structure spectrally. Using biochemical, molecular biology, immunostaining and transmission electron microscopy (TEM) methods, we studied DDQ's beneficial effects in AD neurons. We measured the levels of Aβ and Drp1, Aβ and Drp1 interaction, mRNA and protein levels of mitochondrial dynamics, biogenesis and synaptic genes, mitochondrial function and cell viability and mitochondrial number in DDQ-treated and untreated AD neurons. Our qRT-PCR and immunoblotting analysis revealed that reduced levels of mitochondrial fission and increased fusion, biogenesis and synaptic genes in DDQ-treated AD neurons. Our immunoblotting and immunostaining analyses revealed that Aβ and Drp1 levels were reduced in DDQ-treated AD neurons. Interaction between Aβ and Drp1 is reduced in DDQ-treated AD neurons. Aβ42 levels were significantly reduced in DDQ-treated mutant APPSwe/Ind cells. Mitochondrial number is significantly reduced and mitochondrial length is significantly increased. Mitochondrial function and cell viability were maintained in AD neurons treated with DDQ. These observations indicate that DDQ reduces excessive mitochondrial fragmentation, enhances fusion, biogenesis and synaptic activity and reduces Aβ42 levels and protects AD neurons against Aβ-induced mitochondrial and synaptic toxicities.
© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28854701      PMCID: PMC5886305          DOI: 10.1093/hmg/ddx226

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  46 in total

1.  Intraneuronal Abeta42 accumulation in human brain.

Authors:  G K Gouras; J Tsai; J Naslund; B Vincent; M Edgar; F Checler; J P Greenfield; V Haroutunian; J D Buxbaum; H Xu; P Greengard; N R Relkin
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

2.  Dynasore, a cell-permeable inhibitor of dynamin.

Authors:  Eric Macia; Marcelo Ehrlich; Ramiro Massol; Emmanuel Boucrot; Christian Brunner; Tomas Kirchhausen
Journal:  Dev Cell       Date:  2006-06       Impact factor: 12.270

3.  The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae.

Authors:  Camilla A Hansson Petersen; Nyosha Alikhani; Homira Behbahani; Birgitta Wiehager; Pavel F Pavlov; Irina Alafuzoff; Ville Leinonen; Akira Ito; Bengt Winblad; Elzbieta Glaser; Maria Ankarcrona
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-29       Impact factor: 11.205

Review 4.  Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease.

Authors:  Gunnar K Gouras; Davide Tampellini; Reisuke H Takahashi; Estibaliz Capetillo-Zarate
Journal:  Acta Neuropathol       Date:  2010-03-31       Impact factor: 17.088

5.  Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease.

Authors:  Marcus J Calkins; Maria Manczak; Peizhong Mao; Ulziibat Shirendeb; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2011-08-25       Impact factor: 6.150

Review 6.  Mitochondria and cell bioenergetics: increasingly recognized components and a possible etiologic cause of Alzheimer's disease.

Authors:  Russell H Swerdlow
Journal:  Antioxid Redox Signal       Date:  2011-09-15       Impact factor: 8.401

Review 7.  Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases.

Authors:  P Hemachandra Reddy; Tejaswini P Reddy; Maria Manczak; Marcus J Calkins; Ulziibat Shirendeb; Peizhong Mao
Journal:  Brain Res Rev       Date:  2010-12-08

8.  Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model.

Authors:  Heng Du; Lan Guo; Shiqiang Yan; Alexander A Sosunov; Guy M McKhann; Shirley ShiDu Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-11       Impact factor: 11.205

Review 9.  Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease.

Authors:  Gunnar K Gouras; Claudia G Almeida; Reisuke H Takahashi
Journal:  Neurobiol Aging       Date:  2005-10       Impact factor: 4.673

Review 10.  Multiple faces of dynamin-related protein 1 and its role in Alzheimer's disease pathogenesis.

Authors:  Ramesh Kandimalla; P Hemachandra Reddy
Journal:  Biochim Biophys Acta       Date:  2015-12-17
View more
  19 in total

Review 1.  ROS as Regulators of Mitochondrial Dynamics in Neurons.

Authors:  Carolina Cid-Castro; Diego Rolando Hernández-Espinosa; Julio Morán
Journal:  Cell Mol Neurobiol       Date:  2018-04-23       Impact factor: 5.046

Review 2.  Small molecules as therapeutic drugs for Alzheimer's disease.

Authors:  Darryll M A Oliver; P Hemachandra Reddy
Journal:  Mol Cell Neurosci       Date:  2019-03-12       Impact factor: 4.314

Review 3.  Mitochondrial dynamics regulators: implications for therapeutic intervention in cancer.

Authors:  Sanjay Kumar; Rahail Ashraf; Aparna C K
Journal:  Cell Biol Toxicol       Date:  2021-10-18       Impact factor: 6.691

4.  Protective effects of a small-molecule inhibitor DDQ against tau-induced toxicities in a transgenic tau mouse model of Alzheimer's disease.

Authors:  Murali Vijayan; Mathew George; Lloyd E Bunquin; Chhanda Bose; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2022-03-31       Impact factor: 5.121

5.  Cdk5 Promotes Mitochondrial Fission via Drp1 Phosphorylation at S616 in Chronic Ethanol Exposure-Induced Cognitive Impairment.

Authors:  Dandan Liu; Jiande Li; Xiaoming Rong; Jie Li; Ying Peng; Qingyu Shen
Journal:  Mol Neurobiol       Date:  2022-09-09       Impact factor: 5.682

Review 6.  Reassessment of Pioglitazone for Alzheimer's Disease.

Authors:  Ann M Saunders; Daniel K Burns; William Kirby Gottschalk
Journal:  Front Neurosci       Date:  2021-06-16       Impact factor: 4.677

Review 7.  Defective mitophagy in Alzheimer's disease.

Authors:  Jangampalli Adi Pradeepkiran; P Hemachandra Reddy
Journal:  Ageing Res Rev       Date:  2020-10-03       Impact factor: 10.895

8.  MicroRNA-455-3p as a Potential Biomarker for Alzheimer's Disease: An Update.

Authors:  Subodh Kumar; P Hemachandra Reddy
Journal:  Front Aging Neurosci       Date:  2018-02-23       Impact factor: 5.750

Review 9.  Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer's Disease.

Authors:  P Hemachandra Reddy; Darryll Ma Oliver
Journal:  Cells       Date:  2019-05-22       Impact factor: 6.600

Review 10.  Mitochondrial Dysfunction as a Driver of Cognitive Impairment in Alzheimer's Disease.

Authors:  Chanchal Sharma; Sehwan Kim; Youngpyo Nam; Un Ju Jung; Sang Ryong Kim
Journal:  Int J Mol Sci       Date:  2021-05-03       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.